Wall Street is positive on iTeos Therapeutics Inc (ITOS). On average, analysts give ITOS a Strong Buy rating. The average price target is $43.6, which means analysts expect the stock to decrease by -1.36% over the next twelve months.
That average ranking earns ITOS an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With iTeos Therapeutics Inc Stock Today?
iTeos Therapeutics Inc (ITOS) stock has gained 4.07% while the S&P 500 is down -0.12% as of 3:15 PM on Tuesday, Mar 2. ITOS has risen $1.73 from the previous closing price of $42.47 on volume of 132,787 shares. Over the past year the S&P 500 is higher by 20.44% while ITOS has risen 7266.67%. ITOS lost -$0.88 per share the over the last 12 months.
Click Here to get the full report on iTeos Therapeutics Inc (ITOS) Stock.
